Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [8]. Core Insights - The pharmaceutical sector experienced a decline of 2.67% on March 3, 2025, underperforming the CSI 300 index by 1.13 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [4]. - Notable performances within sub-industries included offline pharmacies (-0.62%), blood products (-1.37%), and in vitro diagnostics (-1.50%), while hospitals (-4.32%), medical R&D outsourcing (-3.53%), and other biological products (-3.39%) lagged behind [4]. - Key individual stock performances included Kanghui Co., Ltd. (+10.01%), Lianhuan Pharmaceutical (+3.89%), and Jiuan Medical (+3.42%) on the gainers' list, while Tianzhihang (-11.45%), Saike Xide (-11.06%), and Wanze Co., Ltd. (-10.01%) were among the biggest losers [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3]. Industry News - Eli Lilly's Lebrikizumab, an anti-IL-13 monoclonal antibody, has received acceptance for market application in China, having previously been approved by the FDA in the U.S. for moderate to severe atopic dermatitis [5]. - Yihong Pharmaceutical's APL-1702 has been approved for the treatment of confirmed CIN2 patients aged 18 and above [5]. - Baiyao's Usymro has received approval from the UK Medicines and Healthcare products Regulatory Agency, enhancing the company's international presence [5]. - Yiling Pharmaceutical's chemical raw material drug, Pomalidomide, has been approved for market application [6]. - Haichuang Pharmaceutical's HP515, a selective THR-β agonist for treating metabolic-associated fatty liver disease, has completed participant enrollment in its Phase IIa clinical trial [6].